Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Kodgule

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The Lancet Regional Health. Southeast Asia|July 5, 2022
SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trialMonika Tandon, Wen Wu, Keith Moore, et al.
The Lancet Regional Health. Southeast Asia|November 14, 2022
Correction to "SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial"Monika Tandon, Wen Wu, Keith Moore, et al.
ERJ Open Research|July 29, 2021
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trialSundeep Salvi, Akash Balki, Srikanth Krishnamurthy, et al.
Lung India : Official Organ of Indian Chest Society|January 11, 2023
Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPDSundeep Salvi, Manish K Jain, Srikanth Krishnamurthy, et al.
Pulmonary Pharmacology & Therapeutics|August 11, 2020
Fixed-dose combination of three drugs, i.e. LABA/LAMA/ICS for COPD: Results of a real-world study from IndiaSundeep Salvi, Ashish Kumar Deb, Mayank Agarwal, et al.
Drugs|March 13, 2020
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled TrialMala Dharmalingam, S R Aravind, Hemant Thacker, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Lancet Regional Health. Southeast Asia|July 5, 2022
SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trialMonika Tandon, Wen Wu, Keith Moore, et al.
The Lancet Regional Health. Southeast Asia|November 14, 2022
Correction to "SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial"Monika Tandon, Wen Wu, Keith Moore, et al.
ERJ Open Research|July 29, 2021
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trialSundeep Salvi, Akash Balki, Srikanth Krishnamurthy, et al.
Lung India : Official Organ of Indian Chest Society|January 11, 2023
Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPDSundeep Salvi, Manish K Jain, Srikanth Krishnamurthy, et al.
Pulmonary Pharmacology & Therapeutics|August 11, 2020
Fixed-dose combination of three drugs, i.e. LABA/LAMA/ICS for COPD: Results of a real-world study from IndiaSundeep Salvi, Ashish Kumar Deb, Mayank Agarwal, et al.
Drugs|March 13, 2020
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled TrialMala Dharmalingam, S R Aravind, Hemant Thacker, et al.
Pageof 2